Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France

Colonna, Marc; Uhry, Zoé; Guizard, Anne‐Valérie; Delafosse, Patricia; Schvartz, Claire; Belot, Aurélien; Grosclaude, Pascale

doi:10.1016/j.canep.2015.04.015

Cited by 95 publications

(70 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, there are many examples of micropapillary carcinomas and incidentally diagnosed tumors in these series whose natural history and impact on acromegaly survival is unknown. This observation is in line with studies in the general population, suggesting that the apparent increase in thyroid cancer incidence can be attributed to a screening effect linked to the use of modern diagnostic tools, which has produced a high number of 'incidentally' discovered less aggressive thyroid tumors (55,56,57).…”

Section: Thyroid Cancersupporting

confidence: 89%

“…At first glance, it seems that thyroid cancer risk in acromegaly has increased considerably in the last decade, but this is unlikely (55,56,57). A cross-sectional analysis comparing a cohort of acromegaly patients with a matched control group usually results in overstated estimates, reflecting the underlying low incidence of the malignancy in the general population (9,28).…”

Section: Thyroid Cancermentioning

confidence: 99%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited

Boguszewski

Ayuk

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

Based on experimental and animal models, epidemiological data from non-acromegaly populations, and longitudinal and cross-sectional cohorts of patients with acromegaly, a potential association between acromegaly and cancer has long been hypothesized, in particular colorectal cancer, and, to a lesser extent, breast, thyroid and prostate cancers. the exact mechanisms underlying this potential association have not been fully elucidated. Results from studies examining cancer incidence and mortality in acromegaly have been inconsistent, with some demonstrating increased risk, whereas others show no increase. this article reviews the existing data relating to cancer risk and mortality in acromegaly, exploring the limitations of study designs and the impact of changes in disease control and patient outcomes over time.

show abstract

Section: Thyroid Cancersupporting

confidence: 89%

Section: Thyroid Cancermentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited

Boguszewski

Ayuk

2016

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Data that confirm the hypothesis of the beneficial selenium supplementation effects in the case of thyroid cancer are rather scarce and apply mainly to its papillary form [99][100][101]. In many studies on animal models, as well as in epidemiological and interventional surveys, beneficial effects were confirmed of normal or even increased serum selenium concentrations on the initiation, progression, and even metastases of various cancer types but not of thyroid cancer [50,102].…”

Section: Prace Poglądowementioning

confidence: 99%

“…Dane o prawdziwości hipotezy odnośnie korzystnego wpływu suplementacji selenem na raka tarczycy są raczej skąpe i dotyczą głównie jego postaci brodawkowatej [99][100][101]. W wielu badaniach na modelach zwierzęcych oraz epidemiologicznych i interwencyjnych stwierdzono korzystny wpływ prawidłowych, a nawet podwyższonych stężeń selenu w surowicy na inicjację, progresję, a nawet przerzuty różnych rodzajów nowotworów, ale nie raka tarczycy [50,102].…”

Section: Prace Poglądoweunclassified

The role of selenium in thyroid gland pathophysiology

Stuss¹,

Michalska-Kasiczak

Sewerynek³

2017

Endokrynologia Polska

View full text Add to dashboard Cite

It is now assumed that proper functioning of the thyroid gland (TG), beside iodine, requires also a number of elements, including selenium, iron, zinc, copper, and calcium. In many cases, only an adequate supply of one of these microelements (e.g. iodine) may reveal symptoms resulting from deficits of other microelements (e.g. iron or selenium). Selenium is accounted to the trace elements of key importance for homeostasis of the human system, in particular, for the proper functioning of the immune system and the TG. Results of epidemiological studies have demonstrated that selenium deficit may affect as many as one billion people in many countries all over the world. A proper sequence of particular supplementations is also worth emphasising for the significant correlations among the supplemented microelements. For example, it has been demonstrated that an excessive supplementation of selenium may enhance the effects of iodine deficit in endemic regions, while proper supplementation of selenium in studied animals may alleviate the consequences of iodine excess, preventing destructive-inflammatory lesions in the TG. This paper is a summary of the current knowledge on the role of selenium in the functionality of the TG.

show abstract

“…tyrosine kinase inhibitors Thyroid cancer (TC) represents the predominant endocrine malignancy (7th most common cause of new cancer in women in the USA (in 2007) and 14th in men). The incidence of papillary thyroid cancer (PTC) has been increasing in the last decade [1][2][3][4].…”

mentioning

confidence: 99%

Sorafenib in the treatment of thyroid cancer

Ferrari

Politti

Spisni

et al. 2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Sorafenib has been evaluated in several Phase II and III studies in patients with locally advanced/metastatic radioactive iodine-refractory differentiated thyroid carcinomas (DTCs), reporting partial responses, stabilization of the disease and improvement of progression-free survival. Best responses were observed in lung metastases and minimal responses in bone lesions. On the basis of these studies, sorafenib was approved for the treatment of metastatic DTC in November 2013. Few studies suggested that reduction of thyroglobulin levels, or of average standardized uptake value at the fluorodeoxyglucose-PET, could be helpful for the identification of responding patients; but further studies are needed to confirm these results. Tumor genetic marker levels did not have any prognostic or predictive role in DTC patients.The most common adverse events observed included skin toxicity and gastrointestinal and constitutional symptoms. Encouraging results have also been observed in patients with medullary thyroid cancer. Many studies are ongoing to evaluate the long-term efficacy and tolerability of sorafenib in DTC patients.

show abstract

Recent trends in incidence, geographical distribution, and survival of papillary thyroid cancer in France

Cited by 95 publications

References 43 publications

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited

The role of selenium in thyroid gland pathophysiology

Sorafenib in the treatment of thyroid cancer

Contact Info

Product

Resources

About